Home Featured Page 296

Featured

Latest

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Awakn Announces Exclusive License Deal with the University of Exeter to...

Can Psilocybin and LSD Relieve Existential Suffering?

PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with...

Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and...

Red Light Holland Launches New Logo and Interactive Wisdom Truffle Companion...

PT233 – JR Rahn of MindMed – LSD, ADHD, and Decriminalization

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

COMPASS Pathways plc to announce fourth quarter and full year 2020...

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine...

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Awakn Announces Exclusive License Deal with the University of Exeter to...

Can Psilocybin and LSD Relieve Existential Suffering?

PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with...

Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and...

Red Light Holland Launches New Logo and Interactive Wisdom Truffle Companion...

PT233 – JR Rahn of MindMed – LSD, ADHD, and Decriminalization

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

COMPASS Pathways plc to announce fourth quarter and full year 2020...

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine...

EDITOR PICKS

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY